Healthcare / Pharmaceutical RetailersSwiss
$7.17
+0.09 (+1.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-118.8M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$349M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-28.6%
↓Gross Margin
21.3%
↓Debt/Equity
0.92
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-16.2%
FCF CAGR
—
FCF margin
-5.4%
FCF / Net income
0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.02B · net income $-97.3M · FCF $-55.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.02B | $1.02B | $969.5M | $931.0M | $1.73B |
| Net Income | $-97.3M | $-97.3M | $82.3M | $-171.1M | $-225.7M |
| EBITDA | $-37.6M | $-37.6M | $-56.1M | $-111.9M | $-159.4M |
| EPS | -4.06 | -4.06 | 3.47 | -7.82 | -11.52 |
| Gross Margin | 21.3% | 21.3% | 21.0% | 17.2% | 15.1% |
| Operating Margin | -10.2% | -10.2% | -8.5% | -16.2% | -11.3% |
| Net Margin | -9.6% | -9.6% | 8.5% | -18.4% | -13.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.92 | 0.92 | 0.77 | 1.51 | 1.08 |
| Current Ratio | 2.19 | 2.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-55.2M | $-55.2M | $-118.8M | $-143.9M | $-194.1M |
| Returns | |||||
| ROE | -28.6% | -28.6% | 19.1% | -48.8% | -46.6% |
| Valuation | |||||
| P/E | — | — | 22.81 | — | — |
| P/B | 0.51 | 0.51 | 2.15 | 0.92 | 4.30 |
| Growth & Yield | |||||
| Revenue Growth | 4.9% | 4.9% | 4.1% | -46.1% | — |
| EPS Growth | -217.0% | -217.0% | 144.4% | 32.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.4%
Start / end P/E
n/dx → n/dx
EPS bridge
3.47 → -4.06
Residual
-24.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.